Hemostemix Company Description

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.

Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function.

The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Hemostemix Inc. is headquartered in Calgary, Canada.

Hemostemix Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
CEO	Thomas Smeenk

Contact Details

Address: 707-7th Avenue SW Calgary, AB T2P 3H6 Canada
Website	hemostemix.com

Stock Details

Ticker Symbol	HEM
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA4236943060
SIC Code	2836

Key Executives

Name	Position
Thomas A. Smeenk B.A., BA Hons	Co-Founder, President, Chief Executive Officer and Director
Christina Wu CPA	Interim Chief Financial Officer
Peter Pavlin	Vice President of Operations
Dr. Fraser C. Henderson Sr., M.D.	Chief Medical Officer